



College of American Pathologists #7186701

CLIA #99D1030993

www.diatech-oncology.com

AML Case Study - DiaTech Oncology

Prepared by Dr. Allan E. Hallquist

Medical Director

February 2007

The patient was a 33 year old male who developed AML. He underwent initial induction therapy with combined idarubicin and Ara-C without the benefit of a MiCK assay. When the idarubicin dose was decreased and the Ara-C dose was maintained the patient immediately relapsed with bone marrow and skin involvement. At this time a MiCK assay was performed on the patient's blood. The MiCK assay identified the blasts as being sensitive to idarubicin but resistant to Ara-C. The patient was then treated with idarubicin only and achieved complete remission with a normal WBC and no skin lesions. The patient remained in remission for 8 months then relapsed in the marrow and skin again. He was empirically treated with idarubicin but failed to respond and died of his disease shortly thereafter.